Fibrinogen receptors inhibition

Horstrup, K., Jablonka, B., Honig-Liedl, P., Just, M., Kochsiek, K., and Walter, U. (1994). Phosphorylation of the focal adhesion protein VASP at Ser 157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur. ]. Biochem. 225, 21-27. 

An in vitro or ex vivo measure of drug effect, for example, mean inhibitory concentration (MIC) of an antimicrobial against bacterial culture inhibition of ADP-induced platelet aggregation with a fibrinogen receptor antagonist. 

Blockers/inhibitors of platelets receptors GP Ilb/IIIa (integrin allb(33) (abeiximab, tirofiban, eptifibatide) Prevent the link of fibrinogen with platelet receptors inhibiting platelet aggregation in front of different agonists... 

Mechanism of Action A glycoprotein Ilb/IIIa receptor inhibitor that rapidly inhibits platelet aggregation by preventing the binding of fibrinogen to GP Ilb/IIIa receptor sites on platelets. Therapeutic Effect Prevents closure of treated coronary arteries. Prevents acute cardiac ischemic complications. 

Mechanism of Action An aggregation inhibitor that inhibits the release of adenosine diphosphate from activated platelets, which prevents fibrinogen from binding to glycoprotein Ilb/IIIa receptors on the surface of activated platelets. TherapeuticEffect Inhibits platelet aggregation and thrombus formation. 

---